依那普利在婴儿中的安全性:儿科心脏网络单心室婴儿试验数据
该双盲试验将230例单心室生理婴儿随机分配至依那普利组或安慰剂组,随访至14月龄。结果显示两组在血压变化、高钾血症和中性粒细胞减少发生率上无显著差异;依那普利组肾功能障碍发生率为3%,安慰剂组为0%,但无统计学意义;两组心脏移植或死亡频率无差异。结论认为血管紧张素转换酶抑制剂在显著心脏病婴儿中安全性风险较低。
要点
- 依那普利起始剂量0.10 mg/kg/d,中位最大剂量0.38 mg/kg/d,两组血压变化无显著差异。
- 高钾血症和中性粒细胞减少发生率两组无差异;肾功能障碍依那普利组3% vs 安慰剂组0%,无统计学意义。
- 两组严重不良事件频率均高,但心脏移植或死亡频率无差异。
核心结论
- 依那普利在单心室婴儿中未显示持续血流动力学效应,安全性风险较低。
研究设计与样本
- 儿科心脏网络开展的双盲试验,纳入230例单心室生理婴儿,随机分配至依那普利组或安慰剂组各115例,随访至14月龄。
主要发现
- 起始或恢复研究药物时血压变化两组无显著差异。
- 高钾血症和中性粒细胞减少发生率两组无差异。
- 肾功能障碍依那普利组3%,安慰剂组0%,无统计学意义。
- 两组严重不良事件频率均高,心脏移植或死亡频率无差异。
关键数值与推荐
- 依那普利初始剂量0.10 mg/kg/d,中位最大剂量0.38 mg/kg/d。
- 肾功能障碍发生率依那普利组3%,安慰剂组0%,无统计学显著性。
临床怎么用
- 在显著心脏病婴儿中使用血管紧张素转换酶抑制剂时,需监测肾功能和血钾,但整体安全性风险较低。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the safety profile of angiotensin-converting enzyme inhibitor therapy in infants with single ventricle. STUDY DESIGN: The Pediatric Heart Network conducted a double-blind trial involving infants with single ventricle physiology randomized to receive enalapril or placebo and followed to 14 months of age. Data including demographics, drug administration, hemodynamic monitoring, laboratory measurements, adverse events, and survival were extracted from the public use data set and compared between the placebo and enalapril-treated groups. RESULTS: The Infant Single Ventricle trial randomized 230 patients, with 115 patients in each group. Initial enalapril dose was 0.10 mg/kg/d and median maximal dose was 0.38 mg/kg/d. There was no significant difference in change in blood pressure at study drug initiation or when resuming study drug after Glenn surgery. The incidence of hyperkalemia and neutropenia did not differ between groups. Renal dysfunction occurred in 3% of the enalapril group and none of the placebo patients, which was not statistically significant. There was a high frequency of serious adverse events in both groups. There was no difference in the frequency of heart transplant or death between groups. CONCLUSIONS: Enalapril did not have sustained hemodynamic effects at initiation or up-titration of drug. Creatinine and potassium were not different between groups, although renal dysfunction occurred more often in the patients on enalapril. Although efficacy of enalapril in neonates with single ventricle has not been demonstrated, the safety profile of angiotensin-converting enzyme inhibitors appears to be low risk in infants and children with significant heart disease.
引用
- Mathur K, Hsu DT, Lamour JM, et al. Safety of Enalapril in Infants: Data from the Pediatric Heart Network Infant Single Ventricle Trial. J Pediatr. 2020. PMID: 32768465. doi:10.1016/j.jpeds.2020.07.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。